Ruthenium complexes can target determinants of tumour malignancy.
Metastases are more decisive for tumour prognosis than primary lesions, because of their multiple locations, low accessibility to surgery and/or radiotherapy, and generally poor responsiveness to chemotherapy. The metastasis should therefore be the primary target for drug therapy. Among ruthenium complexes, NAMI-A is a leading compound that shows selective effects for solid tumour metastases related to a mechanism of action involving the inhibition of the processes of tumour invasiveness. NAMI-A opens an avenue to new perspectives in cancer chemotherapy. This includes novel compounds directed at targets selectively expressed by tumour metastases, thus reducing the typical side effects of the current metal-based drugs that are active via their unselective DNA interaction.
Bergamo
A
A
Callerio Foundation Onlus, via A Fleming 22-31, Trieste, Italy.
Sava
G
G
D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry* / Q000627:therapeutic use; D004121:Dimethyl Sulfoxide / Q000031:analogs & derivatives* / Q000737:chemistry / Q000627:therapeutic use; D015195:Drug Design; D006801:Humans; D051379:Mice; D015394:Molecular Structure; D009362:Neoplasm Metastasis / Q000188:drug therapy*; D009942:Organometallic Compounds / Q000737:chemistry* / Q000627:therapeutic use; D012428:Ruthenium / Q000627:therapeutic use*; D017975:Ruthenium Compounds
D000970:Antineoplastic Agents; D009942:Organometallic Compounds; D017975:Ruthenium Compounds; C113661:imidazolium-bis(imidazole)dimethylsulfoxideimidazotetrachlororuthenate(III); D012428:Ruthenium; D004121:Dimethyl Sulfoxide